Trademark Overview
On Friday, July 19, 2024, a trademark application was filed for G GLUCOCHANGE with the United States Patent and Trademark Office. The USPTO has given the G GLUCOCHANGE trademark a serial number of 98657966. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Thursday, August 14, 2025. This trademark is owned by Caelus Pharmaceuticals B.V.. The G GLUCOCHANGE trademark is filed in the Pharmaceutical Products and Medical & Beauty Services & Agricultural Services categories with the following description:
Pharmaceutical products for the prevention and treatment of diabetes, hyperglycemia, hypoglycemia, insulin resistance, cardiovascular health, weight management, metabolic syndrome, metabolic imbalance, and related digestive disorders; dietetic foodstuffs and dietetic substances, namely, probiotic supplements, dietary supplements, dietary fibers, functional foods, dietetic foods, dietetic beverages, and nutritional bars adapted for medical use; food supplements and nutritional supplements for human beings; medicinal healthcare preparations for the treatment of diabetes, hyperglycemia, insulin resistance, cardiovascular health, and metabolic disorders including probiotics, synbiotics, natural medicines, and natural remedies for glucose metabolism and metabolic health.
Providing medical and healthcare information in the field of diabetes management, hyperglycemia, cardiovascular health, weight management, metabolic health, and gut health; medical consultation and medical services, namely, telemedicine and remote healthcare by health care professionals via telecommunication networks; Health counselling, health screening services, internet-based health care information services, and medical dietic counseling for the treatment and management of diabetes and metabolic conditions; preparation of reports relating to medical matters, and providing medical diagnostic information to patients and medical practitioners relating to medical information and patient treatment plans; medical testing and analysis for diagnostic purposes; provision of information relating to pharmaceuticals, dietary supplements, and food supplements for diabetes management
